Alnylam Pharmaceuticals (ALNY) Stock Price, Quote, News & History | Benzinga

Alnylam Pharmaceuticals Inc (ALNY) Stock Price, Quote, News & History

ALNYNASDAQ

Trade with Public

Trade with Public

$237.50

8.893.89%

Last update: Aug 19, 12:59 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$234.36

Close

-

Volume / Avg.

642.66K / 1.63M

Day Range

$233.40 - $241.08

52 Wk Range

197.81 - 495.55

Market Cap

$31.78B

P/E Ratio

39.83

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

4.78%

Days to Cover

2.18

Recent Alnylam Pharmaceuticals, Inc. News

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.

Avi Kapoor

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.

Vandana Singh

Stock Market Today: Microsoft Ignites Chip Rebound as SanDisk Jumps 24%

Microsoft's 43% cloud growth revived the AI trade and lifted chipmakers, but Meta's guidance miss and a 19-year high in 30-year yields capped the rebound.

Piero Cingari

Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views

US stocks gain, Dow up 300 points as tech shares surge 5.3%, Bristol-Myers Squibb beats expectations, Columbus McKinnon and Xerox report strong earnings.

Avi Kapoor

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

911.81M

Investing Cash Flow (TTM)

74.94M

Financing Cash Flow (TTM)

-377.00M

Free Cash Flow (TTM)

819.87M

Capital Expenditure (TTM)

-91.95M

Net Change in Cash (TTM)

609.75M

Analyst Trends and Forecast

3

1

May

2

Jun

10

3

Jul

6

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$28.55B

PE Ratio (TTM)

39.83

PE Ratio (FWD)

26.32

PEG Ratio (TTM)

0.43

PS Ratio (TTM)

6.60

PB Ratio (TTM)

22.59

Earnings Yield % (TTM)

2.51%

Earnings Yield % (FWD)

3.80%

EV / EBITDA (TTM)

25.83

Price / EBITDA (TTM)

28.70

Price / Free Cash Flow (TTM)

38.68

Book Value / Share

$10.12

Company Debt

Total Debt

$1.01B

LT Debt

$1.01B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$1.71B

Debt to Equity

0.94

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$234.36

Close

-

Volume / Avg.

642.66K / 1.63M

Day Range

$233.40 - $241.08

52 Wk Range

197.81 - 495.55

Market Cap

$31.78B

P/E Ratio

39.83

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

4.78%

Days to Cover

2.18

About

Sector

Health Care

Industry

Biotechnology

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi thera...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Alnylam Pharmaceuticals (ALNY) stock?

A

You can purchase shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Alnylam Pharmaceuticals (ALNY) competitors?

A

Other companies in Alnylam Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Alnylam Pharmaceuticals (ALNY) stock?

A

Alnylam Pharmaceuticals has a consensus price target of $420.81.

Q

What is the current price for Alnylam Pharmaceuticals (ALNY)?

A

The stock price for Alnylam Pharmaceuticals (NASDAQ: ALNY) is $237.5 last updated August 19, 2026 at 12:59 PM EDT.

Q

Does Alnylam Pharmaceuticals (ALNY) pay a dividend?

A

There are no upcoming dividends for Alnylam Pharmaceuticals.

Q

When is Alnylam Pharmaceuticals (NASDAQ:ALNY) reporting earnings?

A

Alnylam Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Alnylam Pharmaceuticals (ALNY) going to split?

A

There is no upcoming split for Alnylam Pharmaceuticals.

Q

What sector and industry does Alnylam Pharmaceuticals (ALNY) operate in?

A

Alnylam Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.